Phase I Study of High Efficient Killing Cell Therapy for Advanced Non Small Cell Lung Cancer
Who is this study for? Patients with Non-small Cell Lung Cancer
What treatments are being studied? High Efficient Killing Cell Therapy
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Male or female patients' age from 18 years to 70 years.
• Patients who have a life expectancy of at least 3 months.
• pathologically confirmed non-small cell lung cancer.
• failed in previous standard chemotherapy and targeted therapy.
• Karnofsky performance status 0-1.
• adequate organ functions.
Locations
Other Locations
China
Ruijin Hospital
RECRUITING
Shanghai
Contact Information
Primary
Lei H Du, M.S
sealing821201@hotmail.com
13918570392
Time Frame
Start Date: 2017-09-14
Estimated Completion Date: 2025-05-01
Participants
Target number of participants: 15
Treatments
Experimental: HEKT cell
Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
Related Therapeutic Areas
Sponsors
Collaborators: Shanghai Houchao Biotechnology Co., Ltd
Leads: Ruijin Hospital